Related by context. All words. (Click for frequent words.) 69 indolent follicular non 67 previously untreated follicular 66 cell malignancies 65 MyVax R 65 systemic anaplastic large 65 remission induction 65 dasatinib Sprycel 65 cutaneous T 64 relapsed refractory multiple myeloma 64 recurrent NSCLC 64 oral ridaforolimus 64 HER2 positive metastatic breast 64 indolent NHL 64 registrational trial 64 refractory chronic lymphocytic 64 erlotinib Tarceva ® 64 alvespimycin 63 SPRYCEL ® 63 IMA# 63 antibody MAb 63 Intravenous CP 63 oral prodrug 63 forodesine 63 multiple myeloma MM 63 humanized anti 63 refractory indolent non 63 Bezielle 63 Epratuzumab 63 follicular Non Hodgkin 63 investigational monoclonal antibody 63 metastatic hormone refractory 62 paclitaxel Taxol ® 62 Amrubicin 62 cutaneous T cell 62 B CLL 62 docetaxel Taxotere R 62 castrate resistant prostate cancer 62 advanced metastatic renal 62 YONDELIS 62 Gleevec resistant 62 Panzem R NCD 62 OvaRex R 62 CYT# potent vascular disrupting 62 novel histone deacetylase 62 gemcitabine Gemzar ® 62 receptor tyrosine kinase inhibitor 62 Phase #b/#a clinical 62 relapsed refractory 62 glioblastoma multiforme GBM 62 phase IIb trial 62 lintuzumab 62 leukemia CLL 62 PXD# 62 cell lymphoma CTCL 62 xenograft models 61 cell chronic lymphocytic 61 Temsirolimus 61 Fludara ® 61 metastatic renal cell 61 sunitinib malate 61 radiation chemoradiation 61 obatoclax 61 investigational humanized monoclonal antibody 61 PI3K/Akt pathway inhibitor 61 Quinamed 61 Kit CD# positive 61 paclitaxel Taxol R 61 follicular NHL 61 metastatic renal cell carcinoma 61 Hodgkin lymphoma NHL 61 imatinib Gleevec 61 trastuzumab Herceptin R 61 follicular lymphoma 61 Zenvia ™ 61 mRCC 61 adecatumumab 61 cilengitide 61 TRISENOX 61 oncolytic virus therapies 61 metastatic castration resistant 61 Cutaneous T 61 FOLOTYN ® 61 relapsed MM 61 targeted antifolate 61 registrational 61 HCD# [002] 61 ELACYT 61 Peginterferon alfa 2b 61 lymphoid malignancies 61 refractory cutaneous T 61 refractory AML 61 zanolimumab 61 Phase Ib II 61 pediatric acute lymphoblastic 61 Acute Myeloid Leukemia AML 60 gastrointestinal stromal tumor GIST 60 HGS# 60 recurrent glioblastoma multiforme 60 myelofibrosis polycythemia vera 60 Clofarabine 60 Insegia 60 Pralatrexate 60 Phase IIb clinical trials 60 cell acute lymphoblastic 60 Tiuxetan 60 Xanafide 60 evaluating REVLIMID 60 elacytarabine 60 epithelial tumors 60 Fludarabine 60 Omacetaxine 60 bendamustine 60 chemotherapy regimens 60 leukemia AML 60 dasatinib Sprycel ® 60 MAGE A3 ASCI 60 agonistic human 60 ixabepilone 60 CHOP chemotherapy 60 Gleevec imatinib mesylate 60 virus HCV protease inhibitor 60 Diffuse Large B 60 neratinib 60 ara C 60 rALLy clinical trial 60 Virulizin ® 60 visilizumab 60 PEGylated Fab fragment 60 hormone refractory 60 stage IIIb IV 60 Trastuzumab 60 HGS ETR1 60 lumiliximab 60 pan HDAC inhibitor 60 Pertuzumab 60 Nexavar ® 60 cetuximab Erbitux R 60 systemic ALCL 60 Hodgkin lymphoma HL 60 temsirolimus 60 IgG1 monoclonal antibody 60 Aflibercept 60 evaluating picoplatin 60 HuLuc# 60 standard chemotherapy regimen 60 vaccines oncolytic virus 60 gemcitabine carboplatin 60 Ceflatonin 60 cancer immunotherapies 60 Rituximab 60 non metastatic osteosarcoma 60 targeting CD# 60 ZOLINZA 60 refractory NSCLC 60 histologies 59 unresectable stage 59 unique alkylating agent 59 EndoTAGTM 1 59 Cloretazine ® 59 Allovectin 7 R 59 imatinib Gleevec ® 59 relapsed multiple myeloma 59 TroVax ® 59 mapatumumab 59 small lymphocytic lymphoma 59 BAY #-# 59 enzastaurin 59 hormone refractory prostate cancer 59 relapsing remitting MS RRMS 59 Allovectin 7 ® 59 stage IIIB 59 oropharyngeal candidiasis OPC 59 MabCampath 59 ofatumumab 59 CR# vcMMAE 59 phase IIb clinical 59 MCSP respectively 59 concurrent chemoradiation 59 Azedra 59 low dose cytarabine 59 CD# antibody [001] 59 MKC# MT 59 dose escalation clinical 59 rituximab Rituxan 59 KRAS mutant 59 EFAPROXYN 59 Tarceva erlotinib 59 BRAF inhibitor 59 bevacizumab Avastin R 59 OncoVEX GM CSF 59 hematopoietic malignancies 59 Glufosfamide 59 BiovaxID 59 Myelofibrosis 59 Allovectin 7 59 AAG geldanamycin analog 59 PNP inhibitor 59 relapsing multiple sclerosis 59 novel immunotherapies 59 Cloretazine 59 EGFR inhibitors 59 PANVAC VF 59 metastatic colorectal 59 acyclovir Lauriad R 59 Fludara 59 follicular lymphoma FL 59 fluoropyrimidine 59 trastuzumab Herceptin ® 59 Traficet EN 59 imatinib resistant 59 liposomal formulation 59 Relapsed Refractory 59 differentiated thyroid 59 chronic lymphocytic leukemia CLL 59 Pemetrexed 59 ZEVALIN 59 Follicular Lymphoma 59 autologous cellular immunotherapy 59 PSMA ADC 59 Voreloxin 59 thalidomide Thalomid 59 Ozarelix 59 essential thrombocythemia ET 59 luteinizing hormone releasing 59 histone deacetylase HDAC inhibitor 59 anti angiogenic agents 59 galiximab 59 LHRH antagonists 59 hematologic malignancies 59 unresectable Stage III 59 Personalized Immunotherapy 59 generation purine nucleoside 59 Blinatumomab 59 Romidepsin 59 Telatinib 59 metastatic pancreatic 58 Onco TCS 58 Annamycin 58 biologic therapy 58 personalized immunotherapy 58 metastatic castrate resistant 58 relapsed leukemia 58 gefitinib Iressa 58 hematological cancers 58 docetaxel chemotherapy 58 RNAi therapeutic targeting 58 familial amyloidotic polyneuropathy FAP 58 docetaxel Taxotere ® 58 Alemtuzumab 58 OHR/AVR# 58 AVASTIN 58 lymphoma CTCL 58 refractory colorectal cancer 58 mCRC patients 58 recurrent metastatic ovarian cancer 58 sorafenib tablets 58 DLBCL 58 depsipeptide 58 cell lymphoma DLBCL 58 GRNVAC1 58 Daclizumab 58 PEGPH# 58 alkylating agent 58 IMC A# 58 goserelin 58 metastatic colorectal carcinoma 58 Aplidin 58 octreotide implant 58 MGd 58 HDAC Inhibitor 58 generation proteasome inhibitor 58 biliary tract cancer 58 Myocet 58 PROSTVAC TM 58 velafermin 58 IIb clinical trial 58 Evoltra ® 58 metastatic CRC 58 AQ4N 58 heavily pretreated 58 CLL SLL 58 Ixempra 58 custirsen 58 multi kinase inhibitor 58 huN# DM1 58 refractory acute myeloid 58 investigational immunotherapy 58 Anthracycline 58 MyVax ® 58 5 FU leucovorin 58 evaluating T DM1 58 immunotherapeutic 58 Alocrest 58 novel emulsion formulation 58 elotuzumab 58 VitiGam 58 class mGluR5 inhibitor 58 tanespimycin 58 Bortezomib 58 gemcitabine chemotherapy 58 Immunotherapeutic 58 capecitabine Xeloda 58 cytoreduction 58 abiraterone acetate 58 ofatumumab HuMax CD# 58 trastuzumab DM1 T DM1 58 5 fluorouracil leucovorin 58 oral proteasome inhibitor 58 pancreatic NET 58 deforolimus 58 hepatocellular cancer 58 PEG interferon 58 TORISEL 58 regorafenib 58 tyrosine kinase inhibitors 58 refractory systemic anaplastic 58 pegylated liposomal doxorubicin 58 immunomodulatory therapy 58 dextromethorphan quinidine 58 radiation sensitizer 58 Elagolix 58 chemoradiotherapy 58 vidofludimus 58 Velcade bortezomib 58 tiuxetan 58 KRAS wild 58 sorafenib Nexavar 58 advanced carcinoid 58 ALN TTR 58 superficial bladder cancer 58 BCR ABL inhibitors 58 plus DOXIL 58 nab paclitaxel 58 imetelstat 58 AKT inhibitor 58 HGS ETR2 58 apoptosis inducer 58 erlotinib Tarceva 58 herpetic keratitis 58 Glioblastoma Multiforme 58 recurrent metastatic 58 PROSTVAC ® 58 Brentuximab Vedotin SGN 58 cancer neuroendocrine tumor 58 OPAXIO 58 Triapine 58 Pharmacokinetics PK 58 vandetanib 58 BEXXAR 58 gastrointestinal stromal tumors 58 investigational therapies 58 castrate resistant 58 proteasome inhibitor 58 sunitinib Sutent 58 refractory multiple myeloma 58 ibritumomab tiuxetan 58 Xeloda ® 58 FOLFOX6 58 DEB# 58 Xcellerated T Cells 58 Marqibo 58 bevacizumab Avastin ® 58 Cloretazine R 58 PEGylated interferon beta 1a 58 dasatinib 58 atacicept 58 Evoltra R 58 vinca alkaloid 58 TACI Ig 58 Bayer HealthCare Onyx Pharmaceuticals 58 ZACTIMA 58 pomalidomide 58 immunotherapeutic agent 58 allogeneic stem cell 57 aflibercept VEGF Trap 57 Campath alemtuzumab 57 candidates Azedra TM 57 ACTEMRA TM 57 chemoradiation 57 PDX pralatrexate 57 Cell Non Hodgkin 57 panobinostat 57 sunitinib Sutent ® 57 Taxotere docetaxel 57 IMC #B 57 drug conjugate 57 CVP chemotherapy 57 pegylated alpha interferon 57 CTAP# Capsules 57 metastatic HER2 negative 57 Enzastaurin 57 CIMZIA TM 57 Evoltra TM 57 Vidofludimus 57 AEG# 57 castration resistant prostate cancer 57 targeted radiotherapeutic 57 assessing T DM1 57 metastatic malignant melanoma 57 opioid induced constipation OIC 57 3 registrational trial 57 JAK inhibitor 57 paclitaxel Taxol 57 relapsed SCLC 57 idiopathic thrombocytopenic purpura ITP 57 MAA submission 57 PDE4 inhibitor 57 EGFR tyrosine kinase inhibitor 57 pralatrexate injection folate analogue 57 Tarceva TM 57 IV NSCLC 57 Ph + acute lymphoblastic 57 OMNARIS HFA 57 Ibritumomab Tiuxetan 57 XmAb# 57 Mantle Cell Lymphoma 57 baminercept 57 pertuzumab 57 antiangiogenic therapy 57 recurrent malignant glioma 57 nalbuphine ER 57 Cimzia TM 57 recurrent genital herpes 57 lupus nephritis 57 novel peptide 57 HuMax CD4 57 ganetespib 57 antitumor activity 57 platinum refractory 57 HRPC 57 gastrointestinal stromal tumors GIST 57 corticosteroid dexamethasone 57 HBeAg negative 57 otelixizumab 57 tubulin inhibitor 57 Nexavar sorafenib 57 anaplastic thyroid carcinoma 57 recurrent glioblastoma 57 EndoTAG TM -1 57 Cloretazine R VNP#M 57 PROSTASCINT R 57 Troxatyl 57 Copegus ribavirin 57 acute promyelocytic leukemia APL 57 Archexin 57 HGS ETR1 mapatumumab 57 alfa 2a 57 romidepsin 57 Telintra 57 curative resection 57 Hedgehog Pathway Inhibitor 57 PEP# [003] 57 cell carcinoma RCC 57 TTF Therapy 57 leukemia ALL 57 androgen independent 57 irinotecan containing 57 BRIM2 57 novel VDA molecule 57 unresectable locally advanced 57 panitumumab 57 cytarabine 57 Xeloda capecitabine 57 sarcoma melanoma 57 lenalidomide Revlimid R 57 CCR5 antagonist 57 SCCHN 57 Chronic Lymphocytic Leukemia CLL 57 non metastatic resectable 57 TEMODAL 57 MAb 57 DCVax ® Brain 57 MabThera Rituxan 57 VEGFR2 inhibitor 57 Fodosine 57 thymalfasin 57 axitinib 57 FavId 57 LUX Lung 57 docetaxel Taxotere 57 Hsp# Inhibitor 57 Taxotere ® 57 T#I [002] 57 Phase 1b clinical trials 57 chronic myelogenous leukemia CML 57 ospemifene 57 Genasense ® 57 hypereosinophilic syndrome 57 Trastuzumab DM1 57 kidney urologic 57 Carfilzomib 57 EGFR tyrosine kinase inhibitors 57 stage IIIB IV 57 humanized antibody 57 interferon gamma 1b 57 Lenalidomide 57 mertansine 57 dacetuzumab 57 EpCAM 57 tremelimumab 57 pegfilgrastim 57 TELINTRA 57 Onalta ™ 57 Amgen Neulasta R 57 metastatic bladder 57 androgen receptor antagonist 57 lymphoma leukemia 57 refractory prostate cancer 57 CEQ# 57 oral antiviral 57 ponatinib 57 myelodysplastic syndrome MDS 57 fluorouracil 57 OvaRex 57 BCG refractory 57 denileukin diftitox 57 Phase IIIb clinical 57 Vicinium TM 57 EGFR expressing mCRC 57 amrubicin 57 Urocidin 57 Seliciclib 57 HER2 positive 57 intravenous belinostat 57 SUTENT 57 ovarian carcinoma 57 dose cytarabine 57 refractory chronic myeloid 57 completely resected 57 nonsmall cell lung cancer 57 refractory CTCL 57 Phase IIb trials 57 locoregional 57 lenalidomide dexamethasone 57 Chronic Lymphocytic Leukemia 57 Stage IIB 57 Romiplostim 57 Metastatic Melanoma 57 rindopepimut 57 plus gemcitabine 57 recurrent GBM 57 Pegylated Interferon 57 EGFR TKI 57 AGILECT R 57 Phase Ib 57 demonstrated antitumor activity 57 ALN TTR# 57 GW# [003] 57 molecularly targeted 57 OvaRex ® MAb 56 lung pancreatic 56 AA amyloidosis 56 BrachySil TM 56 L BLP# 56 metastatic malignant 56 standard chemotherapy regimens 56 Cerebril TM 56 lymphocytic leukemia 56 myelofibrosis MF 56 chemotherapy cisplatin 56 trabectedin 56 Proxinium TM 56 partial remissions 56 Cell Lymphoma 56 VIDAZA 56 randomized Phase III 56 pediatric malignancies 56 refractory metastatic 56 relapsed mantle 56 Chronic lymphocytic leukemia 56 ISTODAX 56 Follicular lymphoma 56 OMAPRO 56 metastatic ocular 56 oral deforolimus 56 chimeric monoclonal antibody 56 HER2 overexpression 56 huC# DM4 56 paclitaxel poliglumex 56 JVRS 56 chlorambucil 56 refractory Hodgkin 56 farletuzumab 56 acute myelogenous leukemia AML 56 VELCADE melphalan 56 relapsed ovarian cancer 56 eniluracil 56 Plicera 56 gemcitabine Gemzar 56 nucleoside analog 56 IIa trial 56 resistant ovarian cancer 56 DCVax R 56 tumor subtypes 56 metastatic gastric 56 anti CD# antibodies 56 Cell Lung Cancer 56 cyclophosphamide doxorubicin vincristine 56 myeloid metaplasia 56 decitabine 56 adecatumumab MT# 56 Vidaza ® 56 stage IIIb 56 Elotuzumab 56 mCRC 56 chemotherapeutic regimen 56 TO AVOID PREGNANCY WHILE 56 hematological malignancies 56 Chronic lymphocytic leukemia CLL 56 LHRH receptor positive 56 colon carcinoma 56 PegIFN 56 #I TM# 56 oral nucleoside analogue 56 grade cervical intraepithelial 56 SinuNase TM 56 Neulasta ® 56 CBLC# 56 entinostat 56 sapacitabine 56 dose melphalan 56 pemphigus vulgaris 56 liver metastases 56 Dacogen injection 56 daunorubicin 56 viral kinetics 56 metastatic GIST 56 TG# [001] 56 refractory CLL 56 Bosutinib 56 intravesical infusion therapy 56 Solazed TM 56 anticancer compound 56 Hepatocellular Carcinoma HCC 56 CD# monoclonal antibody 56 sarcomatoid 56 Adjuvant Treatment 56 bortezomib Velcade R 56 papillary renal cell carcinoma 56 Rituxan rituximab 56 IMGN# 56 hormone refractory metastatic prostate 56 sorafenib Nexavar ® 56 neoadjuvant treatment 56 CIMZIA ™ 56 Aplidin R 56 cytotoxic chemotherapy 56 predictive biomarker 56 unresectable 56 RITUXAN 56 hematologic cancers 56 pegylated interferons 56 taxane chemotherapy 56 acute leukemias 56 Arsenic trioxide 56 Revimmune 56 ribavirin RBV 56 metastatic RCC 56 Complicated Skin 56 Tesetaxel 56 immunological diseases 56 chronic myeloid leukemia CML 56 malignant pleural mesothelioma 56 Revlimid lenalidomide 56 Campath ® 56 HQK 56 BRAF V# mutation 56 mycosis fungoides 56 dacarbazine 56 liposomal doxorubicin 56 figitumumab 56 estramustine 56 Saforis 56 bortezomib 56 PRT# 56 vinorelbine tartrate 56 carfilzomib 56 Phase III randomized controlled 56 Acute myelogenous leukemia 56 metastatic carcinoma 56 inhaled liposomal ciprofloxacin 56 Degarelix 56 Altastaph 56 CD# antigen 56 palifosfamide 56 surgical debulking 56 trans retinoic acid 56 epratuzumab 56 dirucotide MBP# 56 Ofatumumab 56 tumors GIST 56 veltuzumab 56 metastatic colorectal cancer 56 triphendiol 56 metastatic renal 56 ErbB2 positive 56 Erlotinib 56 etoposide 56 Monoclonal antibody 56 JAK2 inhibitors 56 Nilotinib 56 immune modulating 56 Pazopanib 56 resistant hormone refractory 56 TTR amyloidosis 56 Alessandro Riva 56 corticotropin injection 56 NSCLC 56 prostate cancer HRPC 56 sargramostim 56 Syndrome LEMS 56 carboplatin paclitaxel 56 Philadelphia Chromosome Positive 56 lorvotuzumab mertansine 56 FOLFOX chemotherapy 56 Taxotere chemotherapy 56 INCB# [001] 56 myeloproliferative disorders 56 trastuzumab DM1 56 PEG SN# 56 dacarbazine DTIC 56 Hepatocellular Carcinoma 56 imatinib resistance 56 non squamous 56 etanercept Enbrel 56 nucleotide analog 56 Gastrointestinal Stromal Tumors 56 Advanced Renal Cell 56 FUSILEV enhances 56 anti angiogenic therapy 56 Natalizumab 56 antimetabolite 56 relapsed Acute Myeloid 56 metastatic sarcomas 56 ThermoDox R 56 leading oral taxane 56 Phase Ib clinical 56 VNP#M 56 K ras mutations 55 plus prednisone 55 GV# [001] 55 hoFH 55 ONTAK 55 inhaled antibiotic 55 iniparib 55 cytokine refractory 55 Targretin capsules 55 L asparaginase 55 randomized controlled Phase 55 multicenter Phase II 55 Factor VIIa 55 HDACi 55 squamous non 55 Acute myeloid leukemia 55 ONCASPAR 55 humanized monoclonal antibody 55 haematological cancers 55 immunotherapy treatments 55 FOLOTYN 55 oral clodronate 55 thetreatment 55 initiate multicenter 55 relapsed follicular lymphoma 55 haematologic malignancies 55 Neuvenge 55 EGFr 55 peritoneal carcinomatosis 55 SinuNase 55 FOLFIRI 55 pancreatic adenocarcinoma 55 SNT MC# 55 pegylated interferon alpha 55 chemotherapy docetaxel 55 GRN#L 55 Gleevec imatinib 55 nilotinib Tasigna ® 55 neuroendocrine cancers 55 Achieves Primary Endpoint 55 anticancer therapy 55 antibody MT# 55 doublet chemotherapy 55 acetonide FA 55 Bleomycin 55 tramiprosate Alzhemed TM 55 ISTODAX ® 55 bleomycin 55 hepatitis C HCV 55 BRIM3 55 ONCONASE R 55 cell lymphoma ALCL 55 relapsed acute myelogenous 55 Irinotecan 55 Pegasys ® 55 KRAS status 55 MGCD# [001] 55 Flu Cy 55 refractory Hodgkin lymphoma 55 cathepsin K inhibitor 55 Abiraterone acetate 55 Friedreich Ataxia FRDA 55 rALLy 55 advanced NSCLC 55 Exherin TM 55 Acute Myeloid Leukaemia AML 55 picoplatin 55 HER2 negative 55 refractory metastatic colorectal cancer 55 Hormone Refractory Prostate Cancer 55 Perifosine 55 CCX# 55 Radioimmunotherapy 55 refractory acute promyelocytic 55 allogeneic cell 55 colorectal liver metastases 55 HSP# inhibitor 55 icatibant 55 Doxil ® 55 YONDELIS R 55 dirucotide 55 malignant pleural mesothelioma MPM 55 HCV SPRINT 55 IRX 2 55 XELOX 55 plus prednisone prednisolone 55 PRTX 55 pediatric Crohn disease 55 cisplatin resistant 55 posterior uveitis 55 radioimmunotherapy 55 Phase #/#a trial 55 MEK Inhibitor 55 registrational Phase 55 Talabostat 55 Myelodysplastic Syndrome MDS 55 ALN PCS 55 relapsed acute lymphoblastic 55 therapeutic regimens 55 cyclophosphamide methotrexate 55 myelofibrosis 55 telaprevir dosed 55 Ceplene/IL-2 55 Antigen Specific 55 cisplatin chemotherapy 55 Ceflatonin R 55 GALNS 55 milatuzumab 55 taxane therapy 55 vinorelbine 55 Docetaxel 55 rituximab 55 panitumumab Vectibix 55 pain palliation 55 myelodysplastic myeloproliferative diseases 55 MyVax 55 TELINTRA R 55 neovascular diseases 55 opioid induced bowel dysfunction 55 5-FU/LV 55 bosutinib 55 evaluating Xcytrin 55 Plaque Psoriasis 55 p# biomarker 55 subcutaneous formulation 55 cediranib 55 Vidaza azacitidine 55 IV administered darinaparsin 55 Diabetic Macular Edema DME 55 ER CHOP 55 TREANDA 55 fallopian tube carcinoma 55 rilonacept 55 Navelbine ® 55 anti CD# antibody 55 Castration Resistant Prostate Cancer 55 KRAS mutations occur 55 PROVENGE sipuleucel T 55 nucleoside naive 55 including eniluracil ADH 55 hematological malignancy 55 demethylation agents 55 hA# 55 BEACOPP 55 PROVENGE ® 55 brentuximab vedotin SGN 55 mda 7 55 Metastatic Colorectal Cancer 55 IL# PE#QQR 55 protein kinase inhibitors 55 chronic eosinophilic leukemia 55 tyrosine kinase inhibitor TKI 55 mTOR inhibitor 55 hormone LHRH antagonist 55 TRISENOX ® 55 hepatocellular carcinoma HCC 55 Phase 2a trial 55 squalamine 55 imetelstat GRN#L 55 interferon alfa 55 interferon IFN 55 rituximab refractory 55 tyrosine kinase inhibitor 55 Phase IIb III 55 cisplatin gemcitabine 55 eribulin mesylate 55 predictive biomarkers 55 SIR Spheres 55 adalimumab Humira 55 acute myeloid leukemia AML 55 malignant pheochromocytoma 55 Chronic Myelogenous Leukemia CML 55 leukemia APL 55 proteasome inhibitors 55 Prodarsan R 55 Stage IIIb 55 BCR ABL inhibitor 55 KIACTA ™ 55 Deforolimus 55 humanised monoclonal antibody 55 hepatic metastases 55 cell lymphomas 55 prokinetic agent 55 NSABP B 55 Akt activation 55 BRAF mutation 55 EGFR mutation positive 55 polycythemia vera essential thrombocythemia 55 metastatic liver 55 brand ciclesonide HFA 55 tolevamer 55 Bioral Amphotericin B 55 Tamibarotene 55 radiolabeled TM# 55 ZADAXIN ® 55 refractory ovarian cancer 55 Peginterferon 55 RGB # 55 vorinostat 55 fosbretabulin 55 alefacept 55 vinca alkaloids 55 randomized Phase 2b 55 Lambert Eaton Myasthenic 55 Vandetanib 55 ENMD # 55 TMC# C# 55 adriamycin 55 Meets Primary Endpoint 55 Onconase 55 IV melanoma 55 Onrigin 55 Torisel 55 Squalamine 55 Epidermal Growth Factor Receptor 55 pegylated interferon alfa 2a 55 Mitoxantrone 55 AML acute myeloid 55 LEUKINE 55 tumor xenograft models 55 NXL# 55 Vidaza R 55 castration resistant 55 Jevtana 55 Acute myeloid leukemia AML 55 Ribavirin causes 55 Bendamustine 55 temozolomide 55 immunotherapeutic approaches 55 operable breast cancer 55 K RAS 55 B lymphocyte 55 temozolomide TMZ 55 DOS# 55 metastatic neuroendocrine tumors 55 CYC# 55 refractory gout 55 belinostat 55 immunosuppressive regimens 55 OvaRex MAb 55 invasive candidiasis 55 Zolinza 55 virus HCV infection 55 Initiates Clinical Trial 55 SUCCEED trial 54 Amigal 54 IV metastatic melanoma 54 atypical hemolytic uremic syndrome 54 trastuzumab Herceptin 54 melphalan prednisone 54 imatinib mesylate 54 NPC 1C 54 Omnitarg 54 LEP ETU 54 recurrent ovarian cancer 54 ovarian esophageal 54 Metastatic 54 CRp 54 Paraplatin ® carboplatin 54 boosted protease inhibitor 54 immunomodulator